Key result
Cilengitide plus checkpoint blockade suppresses gastric cancer peritoneal metastasis and reduces T-cell exhaustion.
Why the study?
While periostin contributes to tumor progression and immune regulation, its direct influence on T-cell activity and antitumor immunity remains unclear.
Does targeting POSTN+ CAFs with Cilengitide combined with immunotherapy reduce tumor burden and T-cell exhaustion in a gastric cancer peritoneal metastasis model?
Does targeting POSTN+ CAFs with Cilengitide combined with immunotherapy reduce tumor burden and T-cell exhaustion in a gastric cancer peritoneal metastasis model?
Targeting the POSTN-ICAM-1 axis in cancer-associated fibroblasts has the potential to overcome immunosuppression and enhance the efficacy of immune checkpoint blockade in gastric cancer peritoneal metastasis.
Cilengitide-immunotherapy combinations warrant no clinical use yet; leaves open translation of POSTN-ICAM-1 targeting from gastric cancer models.
Background Periostin (POSTN), an extracellular matrix protein secreted by cancer-associated fibroblasts (CAFs), critically shapes the tumor microenvironment. While POSTN contributes to tumor progression and immune regulation by modifying the microenvironment, its direct influence on T-cell activity and antitumor immunity remains unclear. Methods In this study, single-cell and bulk RNA sequencing datasets were mined and combined with multiplex fluorescence immunohistochemistry to elucidate the role of POSTN + CAFs. Primary CAFs were isolated and fibroblast lines with elevated POSTN expression were established to assess their direct impact on T-cells through functional assays. Transcriptome sequencing identified downstream regulatory pathways in POSTN + CAFs. A mouse peritoneal metastasis model was used to evaluate the therapeutic potential of targeting POSTN + CAFs in combination with immunotherapy. Results Integration of single-cell transcriptomic datasets enabled the construction of a predictive model for gastric cancer peritoneal metastasis (GCPM) based on T-cell exhaustion-associated genes. POSTN was found to be primarily expressed by CAFs in GCPM tissues, with elevated levels correlating with poor clinical outcomes. Functionally, POSTN + CAFs promoted adhesion and spheroid formation by autocrine activation of the AKT-NF-κB-ICAM-1 signaling pathway, facilitating peritoneal dissemination. Co-culture and in vivo experiments suggested that POSTN + CAFs may promote CD8 + T-cell exhaustion via ICAM-1-ETV3 signaling, resulting in diminished effector function and cytokine production. Inhibiting POSTN downstream signaling with the integrin receptor antagonist Cilengitide, especially together with immune checkpoint blockade (anti-PD-1 and anti-CTLA-4), markedly reduced T-cell exhaustion and suppressed GCPM. Conclusion Our results indicate that POSTN + CAFs are pivotal in maintaining an immunosuppressive microenvironment in GCPM. POSTN may facilitates CAFs-tumor and CAFs-T-cell interactions through ICAM-1, thereby promoting metastasis and promoting immune evasion. Targeting the POSTN-ICAM-1 axis may provide a therapeutic approach to enhance immunotherapy efficacy and enhance immunotherapy outcomes in patients with GCPM.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied Gastric cancer peritoneal metastasis. Cilengitide plus immune checkpoint inhibitors (anti-PD-1 and anti-CTLA-4) vs. Vehicle control or anti-PD-1 + anti-CTLA-4 without Cilengitide was evaluated on Peritoneal metastatic tumor burden and CD8+ T-cell exhaustion. Targeting the POSTN-ICAM-1 axis with the integrin receptor antagonist Cilengitide, combined with immune checkpoint blockade, markedly reduced T-cell exhaustion and suppressed gastric cancer peritoneal metastasis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: